GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Other Current Receivables

Syntara (ASX:SNT) Other Current Receivables : A$0.00 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Syntara Other Current Receivables?

Syntara's Other Current Receivables for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Syntara's annual Other Current Receivables increased from Jun. 2021 (A$0.91 Mil) to Jun. 2022 (A$5.18 Mil) and increased from Jun. 2022 (A$5.18 Mil) to Jun. 2023 (A$6.49 Mil).

Syntara Other Current Receivables Historical Data

The historical data trend for Syntara's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syntara Other Current Receivables Chart

Syntara Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.02 5.48 0.91 5.18 6.49

Syntara Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.18 - 6.49 -

Syntara Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

Syntara Other Current Receivables Related Terms

Thank you for viewing the detailed overview of Syntara's Other Current Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Syntara (ASX:SNT) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Syntara Ltd (ASX:SNT) » Definitions » Other Current Receivables
Comparable Companies
ASX:EOF ASX:ECS ASX:RGT ASX:IVX ASX:AGH ASX:IDT ASX:MVP ASX:LGP ASX:EXL ASX:BP8 XTER:MRK ZTS NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ NBIX SZSE:000538 NSE:DIVISLAB
Traded in Other Exchanges
UUDA:Germany
Address
20 Rodborough Road, Locked Bag 5015, Frenchs Forest, Sydney, NSW, AUS, 2086
Website
https://www.pharmaxis.com.au
Syntara Ltd Formerly Pharmaxis Ltd is an Australia based pharmaceutical research company engaged in the research, development, and commercialization of human healthcare products for the treatment and management of fibrotic and inflammatory diseases. The firm's research efforts are focused on discovering drugs to treat inflammatory and fibrotic diseases such as NASH, pulmonary fibrosis, kidney and liver fibrosis and cancer from its amine oxidase inhibitor chemistry platform. Its product pipeline also includes Orbital and ASM8. The operating segments are Mannitol respiratory business and New Drug Development. It generates maximum revenue from Mannitol respiratory business segment.